Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radioactive therapy targets Hard-to-Treat prostate cancer

NCT ID NCT05603559

Recruiting now Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This early-phase study tests a new radioactive drug (177Lu-P17-087/088) in 30 men with advanced prostate cancer that no longer responds to hormone therapy or chemotherapy. The goal is to check safety and find the best dose by giving a single injection and tracking how the drug spreads in the body. Participants must have tumors that show high levels of a specific marker (PSMA) on a PET scan.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER